Literature DB >> 17568811

Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia.

S Mustjoki, T Lundán, S Knuutila, K Porkka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17568811     DOI： 10.1038/sj.leu.2404807

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

Review 1.  Biological therapy and the immune system in patients with chronic myeloid leukemia.

Authors:  Peter Rohon
Journal:  Int J Hematol       Date:  2012-06-04       Impact factor: 2.490

2.  Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

Authors:  Mohamed El Missiry; Shady Adnan Awad; Hanna L Rajala; Ahmed Al-Samadi; Marja Ekblom; Berit Markevän; Ingbritt Åstrand-Grundström; Maren Wold; Ellen Rabben Svedahl; Birgitte Ravn Juhl; Ole Weis Bjerrum; Inger Haulin; Kimmo Porkka; Ulla Olsson-Strömberg; Henrik Hjorth-Hansen; Satu Mustjoki
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-08       Impact factor: 4.553

Review 3.  Does chemotherapy modify the immune surveillance of hematological malignancies?

Authors:  A J Barrett; B N Savani
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

4.  Therapeutic immune monitoring of CD4+CD25+ T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Authors:  Ziyuan Lu; Na Xu; Xuan Zhou; Guanlun Gao; Lin Li; Jixian Huang; Yuling Li; Qisi Lu; Bolin He; Chengyun Pan; Xiaoli Liu
Journal:  Oncol Lett       Date:  2017-06-01       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.